Digital Therapeutics

Digital therapeutic tools to augment or replace traditional therapies.

Lux logo LUX TAKE:

Digital therapeutics can replace or augment current modes of care like pharmaceuticals, physical therapy, or mental health services. They enable the transformation of healthcare by bringing medical care to patients in a scalable, low-cost way, but most companies are in their adolesence and have yet to verify their value proposition. However, with emerging digital dispensaries lowering the bar for ...


Lux Take last updated on June 09, 2021
Data last updated on October 14, 2021

What's New

Lux Research analysts and the Lux Intelligence Engine have added the following recent digital therapeutics developments.

News Commentaries

Psychedelic therapeutics company Cybin applies for patent for digital therapeutics platform (July 21, 2021)

Pear Therapeutics goes public in SPAC deal (June 30, 2021)

New Lux Content

Amalgam Rx (September 28, 2021)

Flint Rehab (August 26, 2021)

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978

© 2004-2021 Lux Research, Inc. All Lux Research content is intended only for consumption by Lux Research clients; redistribution is prohibited and copyright is strictly enforced. All material is based on information obtained from sources believed to be reliable but no independent verification has been made, nor is its accuracy or completeness guaranteed. All material is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments.